Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPEDE-PKD: Metformin in Early Stage ADPKD
NCT04939935Phase 3Recruiting
- Sponsor
- The University of Queensland
- Start
- Nov 2022
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of metformin in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by The University of Queensland. Primary endpoint: Change in estimated glomerular filtration rate at 24 months. Started Nov 2022; status: recruiting.
02
Drugs
metformin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04939935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939935.